Literature DB >> 22720227

Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2.

Emmanuelle Godefroy1, Nina Bhardwaj.   

Abstract

The matrix metalloproteinase-2 (MMP-2), overexpressed in most cancers, induces TH2 polarization by conditioning dendritic cells to over-express OX40L and downregulate IL-12p70 through the degradation of the type-I IFN receptor IFNAR1. Elucidating mechanisms underlying detrimental tumor-associated type-2 responses represent a crucial step in designing effective immune therapies to treat cancer patients.

Entities:  

Year:  2012        PMID： 22720227      PMCID： PMC3376966          DOI： 10.4161/onci.1.1.17994

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

Review 2.  Dendritic cell regulation of TH1-TH2 development.

Authors:  M Moser; K M Murphy
Journal:  Nat Immunol       Date:  2000-09       Impact factor: 25.606

3.  A mechanism for the initiation of allergen-induced T helper type 2 responses.

Authors:  Caroline L Sokol; Gregory M Barton; Andrew G Farr; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2008-03       Impact factor: 25.606

4.  Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment.

Authors:  Takanori So; Jianxun Song; Katsuji Sugie; Amnon Altman; Michael Croft
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-24       Impact factor: 11.205

5.  Cytokine production by peripheral lymphocytes in melanoma.

Authors:  Rafael Botella-Estrada; Marta Escudero; José E O'Connor; Eduardo Nagore; Bernardo Fenollosa; Onofre Sanmartín; Celia Requena; Carlos Guillén
Journal:  Eur Cytokine Netw       Date:  2005 Jan-Mar       Impact factor: 2.737

Review 6.  Matrix metalloproteinases in human melanoma.

Authors:  U B Hofmann; J R Westphal; G N Van Muijen; D J Ruiter
Journal:  J Invest Dermatol       Date:  2000-09       Impact factor: 8.551

7.  Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.

Authors:  Emmanuelle Godefroy; Olivier Manches; Brigitte Dréno; Tsivia Hochman; Linda Rolnitzky; Nathalie Labarrière; Yannick Guilloux; Judith Goldberg; Francine Jotereau; Nina Bhardwaj
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

8.  Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.

Authors:  L Lauerova; L Dusek; M Simickova; I Kocák; M Vagundová; J Zaloudík; J Kovarík
Journal:  Neoplasma       Date:  2002       Impact factor: 2.575

9.  TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand.

Authors:  Tomoki Ito; Yui-Hsi Wang; Omar Duramad; Toshiyuki Hori; Guy J Delespesse; Norihiko Watanabe; F Xiao-Feng Qin; Zhengbin Yao; Wei Cao; Yong-Jun Liu
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

10.  Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307
  10 in total
  6 in total

Review 1.  Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.

Authors:  Mansi Saxena; Nina Bhardwaj
Journal:  Trends Cancer       Date:  2018-02

2.  CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.

Authors:  Lena M Kranz; Matthias Birtel; Christina Krienke; Christian Grunwitz; Jutta Petschenka; Kerstin C Reuter; Niels van de Roemer; Fulvia Vascotto; Mathias Vormehr; Sebastian Kreiter; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2015-07-17       Impact factor: 3.452

Review 3.  Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

Authors:  Fei Xiong; Qi Wang; Guan-Hua Wu; Wen-Zheng Liu; Bing Wang; Yong-Jun Chen
Journal:  Biomark Res       Date:  2022-09-14

4.  MMP2 and TLRs modulate immune responses in the tumor microenvironment.

Authors:  Luciana R Muniz-Bongers; Christopher B McClain; Mansi Saxena; Gerold Bongers; Miriam Merad; Nina Bhardwaj
Journal:  JCI Insight       Date:  2021-06-22

5.  Melanoma hijacks plasmacytoid dendritic cells to promote its own progression.

Authors:  Caroline Aspord; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

Review 6.  P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.

Authors:  Arjelle Decasa Agupitan; Paul Neeson; Scott Williams; Jason Howitt; Sue Haupt; Ygal Haupt
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.